AIM
LXRX icon

Advantage Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Advantage Investment Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$2K – 1078
2017
Q2 		$2K Hold
100
– – ﹤0.01% 962
2017
Q1 		$1K Buy
+100
New +$1.48K ﹤0.01% 940

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.41% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Advantage Investment Management's LXRX Position: Q3 2017 in Review

Advantage Investment Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2017, closing a stake of 100 shares — an estimated $2K sold.

Advantage Investment Management first reported a position in LXRX in Q1 2017 and held it in 2 quarters. The position peaked at $2K in Q2 2017. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2017.

  • Advantage Investment Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Advantage Investment Management sold 100 Lexicon Pharmaceuticals shares in Q3 2017, an estimated $2K.
  • Advantage Investment Management first reported a position in Lexicon Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Advantage Investment Management's Lexicon Pharmaceuticals position peaked at $2K in Q2 2017.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2017.

Based on Advantage Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.